Semicarbazide-sensitive amine oxidase (SSAO)

Present and future

K. Magyar, Zsuzsa Mészáros

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Although the existence of plasma and tissue-bound semicarbazide-sensitive amine oxidases (SSAOs) has been recognised for a long time, the physiological relevance of these enzymes still remains uncertain. The ability of SSAO to metabolise various aliphatic and aromatic monoamines differs between species, which limits the predictive value of the animal studies for human tissues. SSAO plays a protective role because the oxidative deamination of monoamines reduces their pharmacological activities. However, the products of deamination may be toxic. Several observations indicated that the plasma and tissue SSAO activities differ in certain disease states. It is proposed that selective inhibitors, of low toxicity, might be protective, through inhibiting the formation of the toxic products and the countering the disease-related elevation of SSAO activity. We reported earlier that there was a significant correlation between the serum SSAO activity and severity of atherosclerosis, as well as the intima-media thickness and serum cholesterol levels. Thus SSAO activity might be a clinical marker in the prognostic evaluation of diabetic-vascular complications. Although molecular biological studies are providing more and more reliable knowledge about the enzyme structure, many more studies should be carried out in different disease states are necessary to discover the clinical meaning of the enzyme function.

Original languageEnglish
Pages (from-to)165-173
Number of pages9
JournalInflammopharmacology
Volume11
Issue number2
DOIs
Publication statusPublished - 2003

Fingerprint

Amine Oxidase (Copper-Containing)
Deamination
Poisons
Enzymes
Diabetic Angiopathies
Serum
Atherosclerosis
Biomarkers
Cholesterol
Pharmacology

Keywords

  • Atherosclerosis
  • Diabetes mellitus
  • Parkinson's disease
  • Retinopathy
  • Varicose veins

ASJC Scopus subject areas

  • Pharmacology
  • Immunology

Cite this

Semicarbazide-sensitive amine oxidase (SSAO) : Present and future. / Magyar, K.; Mészáros, Zsuzsa.

In: Inflammopharmacology, Vol. 11, No. 2, 2003, p. 165-173.

Research output: Contribution to journalArticle

Magyar, K. ; Mészáros, Zsuzsa. / Semicarbazide-sensitive amine oxidase (SSAO) : Present and future. In: Inflammopharmacology. 2003 ; Vol. 11, No. 2. pp. 165-173.
@article{616e871e86fa41a7862ca46deacaadaa,
title = "Semicarbazide-sensitive amine oxidase (SSAO): Present and future",
abstract = "Although the existence of plasma and tissue-bound semicarbazide-sensitive amine oxidases (SSAOs) has been recognised for a long time, the physiological relevance of these enzymes still remains uncertain. The ability of SSAO to metabolise various aliphatic and aromatic monoamines differs between species, which limits the predictive value of the animal studies for human tissues. SSAO plays a protective role because the oxidative deamination of monoamines reduces their pharmacological activities. However, the products of deamination may be toxic. Several observations indicated that the plasma and tissue SSAO activities differ in certain disease states. It is proposed that selective inhibitors, of low toxicity, might be protective, through inhibiting the formation of the toxic products and the countering the disease-related elevation of SSAO activity. We reported earlier that there was a significant correlation between the serum SSAO activity and severity of atherosclerosis, as well as the intima-media thickness and serum cholesterol levels. Thus SSAO activity might be a clinical marker in the prognostic evaluation of diabetic-vascular complications. Although molecular biological studies are providing more and more reliable knowledge about the enzyme structure, many more studies should be carried out in different disease states are necessary to discover the clinical meaning of the enzyme function.",
keywords = "Atherosclerosis, Diabetes mellitus, Parkinson's disease, Retinopathy, Varicose veins",
author = "K. Magyar and Zsuzsa M{\'e}sz{\'a}ros",
year = "2003",
doi = "10.1163/156856003765764335",
language = "English",
volume = "11",
pages = "165--173",
journal = "Inflammopharmacology",
issn = "0925-4692",
publisher = "Birkhauser Verlag Basel",
number = "2",

}

TY - JOUR

T1 - Semicarbazide-sensitive amine oxidase (SSAO)

T2 - Present and future

AU - Magyar, K.

AU - Mészáros, Zsuzsa

PY - 2003

Y1 - 2003

N2 - Although the existence of plasma and tissue-bound semicarbazide-sensitive amine oxidases (SSAOs) has been recognised for a long time, the physiological relevance of these enzymes still remains uncertain. The ability of SSAO to metabolise various aliphatic and aromatic monoamines differs between species, which limits the predictive value of the animal studies for human tissues. SSAO plays a protective role because the oxidative deamination of monoamines reduces their pharmacological activities. However, the products of deamination may be toxic. Several observations indicated that the plasma and tissue SSAO activities differ in certain disease states. It is proposed that selective inhibitors, of low toxicity, might be protective, through inhibiting the formation of the toxic products and the countering the disease-related elevation of SSAO activity. We reported earlier that there was a significant correlation between the serum SSAO activity and severity of atherosclerosis, as well as the intima-media thickness and serum cholesterol levels. Thus SSAO activity might be a clinical marker in the prognostic evaluation of diabetic-vascular complications. Although molecular biological studies are providing more and more reliable knowledge about the enzyme structure, many more studies should be carried out in different disease states are necessary to discover the clinical meaning of the enzyme function.

AB - Although the existence of plasma and tissue-bound semicarbazide-sensitive amine oxidases (SSAOs) has been recognised for a long time, the physiological relevance of these enzymes still remains uncertain. The ability of SSAO to metabolise various aliphatic and aromatic monoamines differs between species, which limits the predictive value of the animal studies for human tissues. SSAO plays a protective role because the oxidative deamination of monoamines reduces their pharmacological activities. However, the products of deamination may be toxic. Several observations indicated that the plasma and tissue SSAO activities differ in certain disease states. It is proposed that selective inhibitors, of low toxicity, might be protective, through inhibiting the formation of the toxic products and the countering the disease-related elevation of SSAO activity. We reported earlier that there was a significant correlation between the serum SSAO activity and severity of atherosclerosis, as well as the intima-media thickness and serum cholesterol levels. Thus SSAO activity might be a clinical marker in the prognostic evaluation of diabetic-vascular complications. Although molecular biological studies are providing more and more reliable knowledge about the enzyme structure, many more studies should be carried out in different disease states are necessary to discover the clinical meaning of the enzyme function.

KW - Atherosclerosis

KW - Diabetes mellitus

KW - Parkinson's disease

KW - Retinopathy

KW - Varicose veins

UR - http://www.scopus.com/inward/record.url?scp=0038389838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038389838&partnerID=8YFLogxK

U2 - 10.1163/156856003765764335

DO - 10.1163/156856003765764335

M3 - Article

VL - 11

SP - 165

EP - 173

JO - Inflammopharmacology

JF - Inflammopharmacology

SN - 0925-4692

IS - 2

ER -